ThromboGenics NV (TBGNF) Announces Business Update and 2012 Full-Year Results  
3/15/2013 9:45:00 AM

LEUVEN, Belgium, March 14, 2013 -- /PRNewswire/ -- Transformational 2012 Delivers Euro 30 Million in Net Profit


ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today issued a business update and its financial results for the full year ending December 31, 2012.

The past 12 months have been a defining period for ThromboGenics, resulting in the approval and launch of its lead drug JETREA® (ocriplasmin) in the US. US patients and physicians now have access to the first pharmacological treatment for the sight-threatening condition symptomatic vitreomacular adhesion (VMA). The launch of JETREA® has completed ThromboGenics' transformation into an integrated company with operations in R&D through to full-scale commercialization.